Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05437588 · ClinicalTrials.gov registry record · NA

Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents

A NA study of Depression and Major Depressive Disorder, sponsored by University of Alabama at Birmingham.

Recruiting
Registry status
NA
Development phase
240
Enrollment target
2
Study locations

NCT05437588: Recruiting NA study of Depression and Major Depressive Disorder, sponsored by University of Alabama at Birmingham.

NCT05437588 is a NA study of Depression and Major Depressive Disorder that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 240 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (69% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05437588, a NA study of Depression and Major Depressive Disorder, is actively recruiting participants, sponsored by University of Alabama at Birmingham.

RECRUITING
Registry status
NA
Development phase
240 participants
Enrollment target
2
Study locations

Study Summary

This study is dedicated to help identify biomarkers for depression and suicide. The purpose of the study is to better understand these links to improve medical and psychiatric care in the future. This research is also to test the effects of standard treatment of depression on improvement in depressive and suicidal behavior and on biomarkers (e.g. miRNA) for these disorders.

Conditions Studied

Depression Major Depressive Disorder Suicide Suicide, Attempted Depression in Adolescence MDD Depression, Teen Suicidal Ideas Depression and Suicide

Interventions

  • GENETIC Genetic testing

Study Locations (2)

Alabama

  • University of Alabama at Birmingham - Birmingham
  • UAB Huntsville Regional Medical Campus - Huntsville

Trial Details

FieldValue
Enrollment Target 240 participants
Start Date 2022-10-01
Est. Completion 2027-06-30
Phase NA
University of Alabama at Birmingham

1,160 total trials

What NCT05437588 shows while recruiting

NCT05437588 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (69% lower).

The record links to 9 conditions, with Depression appearing as the primary indexed condition, and to 1 intervention - of which Genetic testing is the first listed.

NCT05437588 reports a single indexed study location in Alabama.

Frequently Asked Questions

What is clinical trial NCT05437588 about?

NCT05437588 is a clinical study titled "Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents". This study is dedicated to help identify biomarkers for depression and suicide. The purpose of the study is to better understand these links to improve medical and psychiatric care in the future. This research is also to test the effects of standard treatment of depression on improvement in depressi...

What is the current status of trial NCT05437588?

This trial is currently recruiting. It is a NA study. The enrollment target is 240 participants. The study started on 2022-10-01. Estimated completion is 2027-06-30.

What conditions does trial NCT05437588 study?

This clinical trial studies the following conditions: Depression, Major Depressive Disorder, Suicide, Suicide, Attempted, Depression in Adolescence.

What interventions are being tested in trial NCT05437588?

The interventions under investigation include: Genetic testing (GENETIC).

Who is sponsoring clinical trial NCT05437588?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05437588 being conducted?

This trial has 2 study locations across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05437588's enrollment target sits among peer trials

240 177th of 679 higher than 494 of 679 other Depression trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02855554 · 240 participants · NA

    Quantitative Cardiac Parametric Mapping

  • NCT03230565 · 240 participants · Phase 4

    Continuous Infusions vs Scheduled Bolus Infusions

  • NCT03399929 · 240 participants

    Traumatic Brain Injury and Stroke Long Term Outcome

  • NCT03583710 · 240 participants · Phase 3

    Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

More recruiting context for NCT05437588

Source: ClinicalTrials.gov NCT05437588, the US trial registry maintained by the National Library of Medicine. NCT05437588 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.